The effects of ginger on fatty liver in type 2 diabetic patients

Phase 3

Recruiting

Conditions: Condition 1: Non-alcoholic fatty liver disease (NAFLD) in patients with type 2 diabetes mellitus. Condition 2: Type 2 diabetes mellitus.
Fatty (change of) liver, not elsewhere classified
Type 2 diabetes mellitus

Registration Number: IRCT20140307016876N3

Lead Sponsor: Shiraz University of Medical Sciences

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Recruiting

Sex: All

Target Recruitment: 70

Inclusion Criteria

The patient with type 2 diabetes mellitus
Fasting blood sugar between 80 and 130 and HbA1C is less than 7%
Age range 25 to 65 years
Body mass index (BMI) ranges from 22 to 35 kg / m 2
The serum alanine transaminase level (ALT) is more than one and a half times higher than normal (ie, in men more than 45 and in women more than or equal to 29 units per liter according to the latest definition of abnormal ALT in men and women)
Having a high-fatty liver disease (moderate to high) in liver ultrasound
Conscious informed consent of patients to participate in the study

Exclusion Criteria

Pregnancy
Liver failure (acute or chronic)
Hepatitis such as autoimmune hepatitis, viral hepatitis B and C (active or inactive), Wilson's disease and ...
Hypo and hyperthyroidism
Renal failure (creatinin above 1.5 mg / dL)
Diabetes-induced retinopathy
Diabetic Nephropathy
alcohol consumption
Any malignancy (treated or not)
Taking warfarin
Taking contraceptives, ursodeoxycholic acid, glucocorticoids, statins, probiotics, vitamin E in the last three months
History of allergy to ginger
Addiction and drug abuse
Heart disease
History of allergy

Study & Design

Study Type: interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
iver aminotrransferase (ALT) Level. Timepoint: Before intervention and three months after the intervention. Method of measurement: Colorimetric method.;Liver fibrosis. Timepoint: Before and three months after the intervention. Method of measurement: Fibrosan (ultrasound waves).

Secondary Outcome Measures